dronabinol oral / Generic mfg. - LARVOL DELTA

Dronabinol After Arthroscopic Surgery (clinicaltrials.gov) - P3 | N=30 | Active, not recruiting | Sponsor: Northwestern University | Trial completion date: Jun 2027 ➔ Jun 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Immunology • Orthopedics • Osteoarthritis • Pain • Rheumatology

Adjunctive dronabinol for quality of life in advanced pancreatic cancer: Results of a randomized, double-blind, placebo-controlled phase III trial (ESMO 2026) - No abstract available

Clinical • HEOR • Metastases • P3 data • Oncology • Pancreatic Cancer • Solid Tumor

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Steven E Harte, PhD | Trial completion date: Oct 2026 ➔ Jun 2027 | Trial primary completion date: Oct 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Polypharmacy, Drug-Drug Interactions and Cannabis Use Among Patients With Oncogene-Driven NSCLC: A Real-World Analysis (IASLC-WCLC 2026) - "Results : Among 223 patients (median age 66.1 years, IQR 57.5-73.8; 61.4% female; 92.4% never/former tobacco users), 22 oral targeted agents were identified, with osimertinib being most common (47.5%)...Most frequent DDI categories were QTc prolongation (11.9%) and CYP3A4 induction driven by concurrent dexamethasone use (16.5%, table 1)...Cannabis use was documented in 29 patients (13.0%), with 10 (4.5%) having active use at TKI initiation, in the form of prescribed dronabinol (9.4%) and 5 (2.2%) with documented non-medical use...These findings highlight the importance of pharmacist-led comprehensive medication/substance review including cannabis use. Prospective studies are needed to investigate the association between polypharmacy, DDIs and cannabis/cannabinoids use with patient-reported outcomes, time on therapy and targeted toxicities."

Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • CYP3A4

Novel pharmacotherapies for opioid use disorder and opioid withdrawal. (PubMed, Front Psychiatry) - "Opioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone...We conducted a narrative review of emerging pharmacologic approaches for OUD and opioid withdrawal syndrome, focusing on ketamine and NMDA receptor antagonists, cannabinoids, psychedelics, and incretin-based therapies, including glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists...Cannabidiol may reduce cue-induced craving and anxiety, whereas dronabinol may modestly suppress opioid withdrawal symptoms...Future studies should prioritize rigorous blinding assessment, active comparators, objective endpoints, standardized cue-reactivity measures, diverse samples, and careful safety monitoring. Regulatory policies should facilitate the development and implementation of future research in novel therapies for OUD."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Mood Disorders • Psychiatry • Substance Abuse

Efficacy of Dronabinol for Obstructive Sleep Apnea: A Systematic Review and Meta-analysis (AAO-HNSF 2026) - "Dronabinol therapy is associated with significant improvements in OSA severity and key sleep continuity metrics, including increased TST, reduced WASO, and improved SE."

Retrospective data • Review • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Synthetic THC And Blood Pressure (clinicaltrials.gov) - P2/3 | N=50 | Not yet recruiting | Sponsor: Mayo Clinic | Initiation date: Jul 2026 ➔ Oct 2026

Trial initiation date

Endocannabinoids in Reward (clinicaltrials.gov) - P2 | N=78 | Not yet recruiting | Sponsor: Medical University of South Carolina

New P2 trial • Substance Abuse

Sex Differences in Neurobehavioral Response to THC (clinicaltrials.gov) - P2 | N=5 | Terminated | Sponsor: Medical University of South Carolina | N=40 ➔ 5 | Trial completion date: Dec 2027 ➔ Aug 2026 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2027 ➔ Aug 2026; Funding status change.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Substance Abuse

BONG: Reducing Breathlessness With Dronabinol in COPD Patients (clinicaltrials.gov) - P3 | N=30 | Active, not recruiting | Sponsor: Vejle Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Pilot study comparing the effects of high dose THC to high dose psilocybin and placebo in the set and setting of a classic psychedelic therapy session. (PubMed, Psychopharmacology (Berl)) - P1 | "These preliminary data suggest that a 25 mg oral dose of pure, synthetic Δ9-THC can be mistaken for a classic hallucinogen, and that oral Δ9-THC can elicit a psychedelic-like experience under set and setting conditions of a typical psychedelic clinical trial. While limited by sample size, these initial results provide insights into the comparative psychopharmacology of Δ9-THC and psilocybin as well as the potentially substantial impact of set and setting on subjective effects of psychoactive drugs."

Journal • Cardiovascular

Dronabinol dämpft Agitation bei Alzheimer-Demenz. (PubMed, MMW Fortschr Med) - No abstract available

Journal • Review • Alzheimer's Disease • CNS Disorders

A Study Of Synthetic THC And Sleep (clinicaltrials.gov) - P2/3 | N=72 | Not yet recruiting | Sponsor: Mayo Clinic | Initiation date: Apr 2026 ➔ Sep 2026

Trial initiation date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Effects of Dronabinol in Opioid Maintained Patients (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Yale University | Trial completion date: Sep 2026 ➔ Jan 2027 | Trial primary completion date: May 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Pain

Dose-related reductions in prefrontal recruitment during cognitive reappraisal following oral delta-9-tetrahydrocannabinol in posttraumatic stress disorder. (PubMed, Neuropsychopharmacology) - "In a randomized, double-blind, placebo-controlled design, adults with PTSD received a single oral dose of placebo (N = 12), 5 mg dronabinol (synthetic THC; N = 12), or 10 mg dronabinol (N = 13) prior to fMRI during a validated cognitive reappraisal task...Exploratory analyses revealed limited correspondence between regional activation and subjective affect. These findings indicate that acute oral THC is associated with dose-dependent reductions in recruitment of prefrontal control circuitry during cognitive reappraisal in PTSD without detectable changes in self-reported affect, consistent with a potential neural-subjective dissociation, although smaller behavioral effects may not have been detectable in the current sample."

Clinical • Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Clinical immunomodulatory effects of cannabinoids in autoimmune diseases in internal medicine : A literature review (PubMed, Rev Med Interne) - "The development of cannabinoid-derived drugs, such as dronabinol, nabiximols, and cannabidiol, is based on two main principles: their role in modulating the release of presynaptic neurotransmitters and their anti-inflammatory and analgesic effects, demonstrated in experimental models and in humans. However, clinical studies evaluating their effects in autoimmune diseases remain scarce. The available, heterogeneous data underscore the need for further basic and clinical research to better characterize these mechanisms and their therapeutic implications."

Journal • CNS Disorders • Epilepsy • Immunology • Inflammatory Arthritis • Lupus • Movement Disorders • Multiple Sclerosis • Neuralgia • Pain • Scleroderma • Systemic Sclerosis • CD4

Safety And Tolerability Of Dronabinol In Alzheimer's Disease: A Bayesian Meta-analysis Of European Randomized Trials (AAIC 2026) - No abstract available

Retrospective data • Alzheimer's Disease • CNS Disorders

Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses. (PubMed, Am J Geriatr Psychiatry) - "Cannabinoid-based therapies showed lower agitation and neuropsychiatric symptom scores than placebo in AD, with somnolence as the main safety concern. Interpretation remains limited by few trials, heterogeneous formulations and outcome instruments, short follow-up, and concentrated statistical weight. Larger randomized trials with formulation-specific protocols, longer follow-up, active comparators, and systematic safety monitoring are needed."

Journal • Retrospective data • Review • Alzheimer's Disease • CNS Disorders • Fatigue • Psychiatry

BONG: Reducing severe Breathlessness with Dronabinol in the severe and very severe chronic obstructive pulmonary disease patient group (clinicaltrialsregister.eu) - P2/3 | N=30 | Active, not recruiting | Sponsor: Lillebaelt Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Hard Pill to Swallow: When Malabsorption Spirals into Myxedema Coma (ENDO 2026) - "Medications included albuterol PRN, aprepitant, diphenhydramine PRN, dronabinol, esomeprazole, fluticasone/umeclidinium/vilanterol, hydrocortisone, hyoscyamine PRN, levothyroxine, midodrine, promethazine PRN, and pyridostigmine. A levothyroxine absorption test can distinguish true malabsorption from non-adherence in patients with refractory hypothyroidism by giving a single large oral dose of levothyroxine followed by serial measurements of thyroid hormone levels over 4-6 hours. This case reinforces that persistent biochemical hypothyroidism with ongoing symptoms should prompt clinicians to consider IV levothyroxine earlier, not only as rescue therapy but as necessary chronic treatment in select patients."

Addiction (Opioid and Alcohol) • Chronic Kidney Disease • Endocrine Disorders • Gastrointestinal Disorder • Hypotension • Musculoskeletal Pain • Nephrology • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone. (PubMed, Pharmacopsychiatry) - "In conclusion, relatively low concentrations may be sufficient to achieve therapeutic effects across all substances studied, with medical cannabis demonstrating these effects at lower concentrations than typically observed in recreational use. Nevertheless, adverse effects at therapeutic reference ranges cannot be excluded."

Journal • Chemotherapy-Induced Nausea and Vomiting • CNS Disorders • Diabetic Neuropathy • Movement Disorders • Multiple Sclerosis • Neuralgia • Pain • Peripheral Neuropathic Pain

Dronabinol for chronic low back pain in Veterans: protocol for a randomized, double-blind, placebo-controlled, parallel-group trial. (PubMed, Pain Manag) - P2 | "Secondary outcomes are exploratory and include pain intensity, physical functioning, emotional functioning, global improvement, analgesic use, and medication adherence. This study is designed to generate safety data and preliminary estimates of variance and effect size to inform a future confirmatory trial; it is not powered to test efficacy hypotheses.Clinical trial registration: http://www.clinicaltrials.gov identifier is NCT06454669."

Clinical • Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Recognition and management patterns of cachexia in patients with pancreatic adenocarcinoma in a safety net hospital. (ASCO 2026) - "FOLFIRINOX (54.5%) and Gemcitabine plus Protein-Bound Paclitaxel (25.8%) were the two most common chemotherapy regimens...11.8% of patients received Dronabinol, 10.2% of patients received Mirtazapine, and 1 patient received Olanzapine... There is a dearth of studies that describe incidence and management patterns of cancer-related cachexia in safety net populations. Cachexia was highly prevalent yet infrequently diagnosed or documented at our institution. A minority of patients with cachexia received pharmaceutical management, while less than half were evaluated by palliative care or nutrition."

Clinical • Cachexia • Oncology • Pancreatic Adenocarcinoma

DEMURE: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (clinicaltrials.gov) - P3 | N=40 | Not yet recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Dec 2027 ➔ May 2028 | Initiation date: May 2026 ➔ Oct 2026 | Trial primary completion date: Dec 2027 ➔ May 2028

Trial completion date • Trial initiation date • Trial primary completion date • Substance Abuse

Systematic review of non-oncologic interventions for neoplastic fever. (ASCO 2026) - "Most studies evaluated non-steroidal anti-inflammatory drugs (NSAIDs); more recent studies investigated dronabinol and tocilizumab. Of the agents that could be synthesized, meta-analysis demonstrated a complete response rate of 86.4% for naproxen (95% CI: 82.2%-90.0%) and 80.0% for indomethacin (95% CI: 70.5%-87.5%)... Current evidence for non-cancer directed pharmacologic treatment of neoplastic fever is limited and largely based on low-quality case studies focused on NSAIDs, which show high apparent response rates. Rigorous, prospective trials are needed to evaluate existing and novel agents for standardized primary and secondary outcomes."

Review • CNS Disorders